Product
Etavopivat
Aliases
Etavopivat A, Etavopivat B, Etavopivat tablets, FT-4202
9 clinical trials
6 indications
Indication
Liver DiseaseIndication
Very Low RiskIndication
Low RiskIndication
Intermediate Risk MDS Per IPSS-RIndication
Sickle Cell DiseaseIndication
ThalassemiaClinical trial
A Pilot Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-06-15
Clinical trial
A Multi-centre, Open-label, Parallel-group Study Investigating the Pharmacokinetics, Safety and Tolerability After a Single Dose of Oral Etavopivat in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Participants With Normal Hepatic FunctionStatus: Not yet recruiting, Estimated PCD: 2025-07-04
Clinical trial
A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-11-03
Clinical trial
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary StrokeStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2026-01-20
Clinical trial
A Single-centre, Open-label, Randomised, Single-dose, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Etavopivat in Healthy ParticipantsStatus: Recruiting, Estimated PCD: 2024-07-06
Clinical trial
An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat StudyStatus: Not yet recruiting, Estimated PCD: 2029-11-30